Contrast Media The Product - Sanochemia

More documents

Recommendations

Info

A Company with Attractive Products CNS / Neurodegeneration The Market for Alzheimer’s Drugs Acetylcholinesterase inhibitors (AChE-I) Drug Marketed / manufactured by API US market share Aricept Pfizer / Eisai donepezil approx. 50% Exelon Novartis rivastigmine approx. 10% Razadyne/ Reminyl J&J, Janssen, Shire galantamine approx. 10% NMDA receptor antagonists (NMDA-I) Drug Marketed / manufactured by API US market share Namenda/ Axura/ Ebixa Forest, Lundbeck, Merz memantine approx. 30% 12
A Company with Attractive Products CNS/Neurodegeneration The Product – GALANTAMINE Product advantages • Purity and availability of consistent API quality vis-à-vis biological galantamine • Proven efficiency of API class established • Additional function of galantamine as a nicotinic receptor modulator Competitive edge • API synthesis process patented until 2014 • Many years development and production experience in this API class Status quo/prospects • Synthetic galantamine as an API (used in Razadyne ® &/ Reminyl ® ) • Use patent expires 2008 in USA and 2012 in Europe 13
Page 1 and 2: Factbook Corporate Profile and Stra
Page 3 and 4: Organisational Chart of SANOCHEMIA
Page 5 and 6: SANOCHEMIA Overview • Our Objecti
Page 7 and 8: SANOCHEMIA Business Model • Devel
Page 9 and 10: SANOCHEMIA Product Strategy A devel
Page 11: A Company with Attractive Products
Page 15 and 16: A Company with Attractive Products
Page 31 and 32: Facts and Figures in T€ Sales rev
Page 33 and 34: Robust Pipeline with High Earnings
Page 35 and 36: Sound Reasons to Invest …in SANOC
Page 37: Contact Investor Relations Margarit

Contrast Media The Product - Sanochemia

Create successful ePaper yourself

Delete template?

Save as template?